HARBOUR BIOMED Revenue and Competitors

Pudong New Area, China

Location

$312.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HARBOUR BIOMED's estimated annual revenue is currently $10.2M per year.(i)
  • HARBOUR BIOMED received $85.0M in venture funding in August 2018.
  • HARBOUR BIOMED's estimated revenue per employee is $77,500
  • HARBOUR BIOMED's total funding is $312.8M.

Employee Data

  • HARBOUR BIOMED has 131 Employees.(i)
  • HARBOUR BIOMED grew their employee count by -2% last year.

HARBOUR BIOMED's People

NameTitleEmail/Phone
1
Founder, Chairman and CEOReveal Email/Phone
2
CTOReveal Email/Phone
3
Chief Development Officer (CDO)Reveal Email/Phone
4
Chief Financial Officer and Chief Business OfficerReveal Email/Phone
5
Chief Strategy OfficerReveal Email/Phone
6
Head Discovery BiologyReveal Email/Phone
7
SVP US OperationsReveal Email/Phone
8
VP, Head BiometicsReveal Email/Phone
9
Senior Director Reveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.2M131-2%$312.8MN/A
#2
$4.2M54N/AN/AN/A
#3
$2.2M57-28%$179.7MN/A
#4
$23.9M309-14%N/AN/A
#5
$0.9M120%N/AN/A
#6
$1.7M220%N/AN/A
#7
$19M245-14%N/AN/A
#8
$9.4M1213%N/AN/A
Add Company

What Is HARBOUR BIOMED?

Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. Learn more about Harbour Biomed: www.harbourbiomed.com/

keywords:N/A

$312.8M

Total Funding

131

Number of Employees

$10.2M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HARBOUR BIOMED News

2022-04-13 - Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical ...

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company";...

2022-04-06 - Harbour BioMed Announces Global Out-License Agreement with ...

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel...

2022-03-22 - Harbour BioMed Reports Full Year 2021 Financial Results ...

and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global...

2021-09-14 - Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) applications for HBM4003, a next-generation ...

2021-09-14 - Harbour BioMed : Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) applications for HBM4003, a next-generation, ...

HARBOUR BIOMED Funding

DateAmountRoundLead InvestorsReference
2018-01-23$UndisclosedA+CDH InvestmentsArticle
2018-08-27$85.0MBGIC Private Limited,Article